# EDGAR Filing Document

**Accession Number:** 0001018735
**File Stem:** 0001640334-25-001988
**Filing Date:** 2025-11
**Character Count:** 2420
**Document Hash:** e8a4131b8637743f505fd5d06beadb78
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001640334-25-001988.hdr.sgml**: 20251107

**ACCESSION NUMBER**: 0001640334-25-001988

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251107

**FILED AS OF DATE**: 20251107

**DATE AS OF CHANGE**: 20251107

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NYMOX PHARMACEUTICAL CORP
- **CENTRAL INDEX KEY:** 0001018735
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12033
- **FILM NUMBER:** 251461546

**BUSINESS ADDRESS:**
- **STREET 1:** 9900 CAVENDISH BLVD., SUITE 306
- **STREET 2:** ST. LAURENT
- **CITY:** QUEBEC CANADA
- **STATE:** A8
- **ZIP:** H4M 2V2
- **BUSINESS PHONE:** 1-800-936-9669

**MAIL ADDRESS:**
- **STREET 1:** 9900 CAVENDISH BLVD., SUITE 306
- **STREET 2:** ST. LAURENT
- **CITY:** QUEBEC CANADA
- **STATE:** A8
- **ZIP:** H4M 2V2

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of **November, 2025**

Commission File Number: 001-12033

---

| |
|:---|
| **Nymox Pharmaceutical Corporation** |
| (Translation of registrant's name into English) |

---

**Bay & Deveaux Streets, Nassau, The Bahamas**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Nymox Pharmaceutical Corporation (the "Company") reports that the U.S. District for the Central District of California granted the Company's and Computershare Investor Services Inc.'s motion to dismiss Christopher Riley's complaint, and dismissed the case, with prejudice.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2025

---

| | |
|:---|:---|
| **NYMOX PHARMACEUTICAL CORPORATION** | **NYMOX PHARMACEUTICAL CORPORATION** |
| By: | /s/ Paul Averback |
| Name: | Paul Averback |
| Title: | President and Chief Executive Officer |

---